885698-71-5

Basic information

• Product Name: 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE
• Synonyms: 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE;1H-Indazole, 6-fluoro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;6-Fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)indazole;(6-FLUORO-1H-INDAZOL-4-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 885698-71-5
• Molecular Formula: C13H16BFN2O2
• Molecular Weight: 262.09
• Mol File: 885698-71-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 407.7±30.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.00±0.40(Predicted)
• CAS DataBase Reference: 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(885698-71-5)
• EPA Substance Registry System: 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(885698-71-5)

Safety Data

• Hazardous Substances Data: 885698-71-5(Hazardous Substances Data)

Usage

General Description

6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE is a chemical compound with the molecular formula C16H19BFNO2. It is a heterocyclic organic compound that contains a fluorine atom and a boron-containing ring structure. 6-FLUORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE may have applications in the field of medicinal chemistry and pharmaceuticals, as well as in organic synthesis and chemical research. It is important to handle this compound with care and to follow proper safety protocols when working with it in a laboratory setting. Its chemical properties and potential uses make it a subject of interest for further study and research in the field of chemistry.

Upstream product

• 502496-36-8 3-bromo-5-fluoro-2-methylbenzenamine 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 73183-34-3 bis(pinacol)diborane 
• 446-10-6 2-nitro-4-fluorotoluene 
• 502496-33-5 1-bromo-5-fluoro-2-methyl-3-nitrobenzene 

Relevant articles and documents

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of Formulas (Ia) and (Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula (Ia) and (Ib) for in vitro, in situ, and in vivodiagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.